全文获取类型
收费全文 | 1940篇 |
免费 | 190篇 |
国内免费 | 16篇 |
专业分类
2146篇 |
出版年
2024年 | 3篇 |
2023年 | 28篇 |
2022年 | 56篇 |
2021年 | 74篇 |
2020年 | 51篇 |
2019年 | 63篇 |
2018年 | 89篇 |
2017年 | 82篇 |
2016年 | 73篇 |
2015年 | 87篇 |
2014年 | 106篇 |
2013年 | 183篇 |
2012年 | 106篇 |
2011年 | 116篇 |
2010年 | 122篇 |
2009年 | 110篇 |
2008年 | 98篇 |
2007年 | 100篇 |
2006年 | 97篇 |
2005年 | 96篇 |
2004年 | 97篇 |
2003年 | 80篇 |
2002年 | 58篇 |
2001年 | 48篇 |
2000年 | 25篇 |
1999年 | 13篇 |
1998年 | 15篇 |
1997年 | 9篇 |
1996年 | 6篇 |
1995年 | 9篇 |
1994年 | 10篇 |
1993年 | 7篇 |
1992年 | 8篇 |
1991年 | 3篇 |
1990年 | 3篇 |
1989年 | 3篇 |
1988年 | 3篇 |
1986年 | 1篇 |
1985年 | 3篇 |
1984年 | 1篇 |
1982年 | 2篇 |
1981年 | 1篇 |
1979年 | 1篇 |
排序方式: 共有2146条查询结果,搜索用时 0 毫秒
991.
992.
The cell cycle and its regulators are validated targets for cancer drugs. Reagents that target cells in a specific cell cycle phase (e.g., antimitotics or DNA synthesis inhibitors/replication stress inducers) have demonstrated success as broad‐spectrum anticancer drugs. Cyclin‐dependent kinases (CDKs) are drivers of cell cycle transitions. A CDK inhibitor, flavopiridol/alvocidib, is an FDA‐approved drug for acute myeloid leukemia. Alzheimer's disease (AD) is another serious issue in contemporary medicine. The cause of AD remains elusive, although a critical role of latent amyloid‐beta accumulation has emerged. Existing AD drug research and development targets include amyloid, amyloid metabolism/catabolism, tau, inflammation, cholesterol, the cholinergic system, and other neurotransmitters. However, none have been validated as therapeutically effective targets. Recent reports from AD‐omics and preclinical animal models provided data supporting the long‐standing notion that cell cycle progression and/or mitosis may be a valid target for AD prevention and/or therapy. This review will summarize the recent developments in AD research: (a) Mitotic re‐entry, leading to the “amyloid‐beta accumulation cycle,” may be a prerequisite for amyloid‐beta accumulation and AD pathology development; (b) AD‐associated pathogens can cause cell cycle errors; (c) thirteen among 37 human AD genetic risk genes may be functionally involved in the cell cycle and/or mitosis; and (d) preclinical AD mouse models treated with CDK inhibitor showed improvements in cognitive/behavioral symptoms. If the “amyloid‐beta accumulation cycle is an AD drug target” concept is proven, repurposing of cancer drugs may emerge as a new, fast‐track approach for AD management in the clinic setting. 相似文献
993.
994.
Maria De Risi Giulia Torromino Michele Tufano Stphanie Moriceau Annabella Pignataro Manon Rivagorda Nicol Carrano Silvia Middei Carmine Settembre Martine Ammassari‐Teule Fabrizio Gardoni Andrea Mele Franck Oury Elvira De Leonibus 《Aging cell》2020,19(9)
Autophagy agonists have been proposed to slow down neurodegeneration. Spermidine, a polyamine that acts as an autophagy agonist, is currently under clinical trial for the treatment of age‐related memory decline. How Spermidine and other autophagy agonists regulate memory and synaptic plasticity is under investigation. We set up a novel mouse model of mild cognitive impairment (MCI), in which middle‐aged (12‐month‐old) mice exhibit impaired memory capacity, lysosomes engulfed with amyloid fibrils (β‐amyloid and α‐synuclein) and impaired task‐induced GluA1 hippocampal post‐translation modifications. Subchronic treatment with Spermidine as well as the autophagy agonist TAT‐Beclin 1 rescued memory capacity and GluA1 post‐translational modifications by favouring the autophagy/lysosomal‐mediated degradation of amyloid fibrils. These findings provide new mechanistic evidence on the therapeutic relevance of autophagy enhancers which, by improving the degradation of misfolded proteins, slow down age‐related memory decline. 相似文献
995.
探究果蝇FADD(Fas-associateddeathdomain-containingprotein)淀粉样蛋白纤维的形成及对IMD(Immune deficiency)信号通路中信号传递的影响,有助于更清楚地了解昆虫先天免疫信号通路中的调节机制,为其他物种的免疫调控提供参考。通过原核表达纯化dFADD蛋白、硫黄素T结合和透射电子显微镜观察等鉴定dFADD在体外纤维的形成;通过构建dFADD真核表达载体,SDD-AGE检测、共聚焦显微镜观察等探究dFADD在果蝇S2细胞内纤维聚合物的形成;构建dFADD结构域突变体,检测纤维形成的关键结构域及对IMD信号传递的影响。结果表明,dFADD在体外和细胞水平上都能聚合形成淀粉样蛋白纤维聚合物;纤维的形成是由dFADD的DED (Death-effector domain)结构域决定的,当DED结构域缺失时,dFADD以单体形式存在;双荧光素酶报告系统的检测结果显示,dFADD只有形成纤维时,才能诱导下游抗菌肽的表达,表明纤维形成是IMD信号传递的关键。本研究揭示了dFADD通过形成淀粉样蛋白纤维参与IMD信号通路中介导IMD与Dredd级联传导的作用,进一步加深了对淀粉样蛋白纤维不仅在哺乳动物,也在昆虫的免疫信号通路中传递信号这一保守功能的认识。 相似文献
996.
《Journal of molecular biology》2021,433(10):166953
Aberrant aggregation and amyloid formation of tar DNA binding protein (TDP-43) and α-synuclein (αS) underlie frontotemporal dementia (FTD) and Parkinson’s disease (PD), respectively. Amyloid inclusions of TDP-43 and αS are also commonly co-observed in amyotrophic lateral sclerosis (ALS), dementia with Lewy bodies (DLB) and Alzheimer disease (AD). Emerging evidence from cellular and animal models show colocalization of the TDP-43 and αS aggregates, raising the possibility of direct interactions and co-aggregation between the two proteins. In this report, we set out to answer this question by investigating the interactions between αS and prion-like pathogenic C-terminal domain of TDP-43 (TDP-43 PrLD). PrLD is an aggregation-prone fragment generated both by alternative splicing as well as aberrant proteolytic cleavage of full length TDP-43. Our results indicate that two proteins interact in a synergistic manner to augment each other’s aggregation towards hybrid fibrils. While monomers, oligomers and sonicated fibrils of αS seed TDP-43 PrLD monomers, TDP-43 PrLD fibrils failed to seed αS monomers indicating selectivity in interactions. Furthermore, αS modulates liquid droplets formed by TDP-43 PrLD and RNA to promote insoluble amyloid aggregates. Importantly, the cross-seeded hybrid aggregates show greater cytotoxicity as compared to the individual homotypic aggregates suggesting that the interactions between the two proteins have a discernable impact on cellular functions. Together, these results bring forth insights into TDP-43 PrLD – αS interactions that could help explain clinical and pathological presentations in patients with co-morbidities involving the two proteins. 相似文献
997.
998.
999.
1000.
《Autophagy》2013,9(4):617-618
Alzheimer disease (AD) is a form of neurodegeneration that develops over the course of multiple decades and as a result of the accumulation of the pathogenic amyloid-β (Aβ) peptide, also known as A4. In late-stage AD, failure of autophagic clearance results in neuronal cell bodies that are almost entirely consumed by autophagic vacuoles (AVs). Previously, we have shown that the potential AD drug latrepirdine (aka Dimebon®), a Russian antihistamine that has shown mixed results in phase II clinical trials in AD, regulates metabolism of the amyloid-β/A4 precursor protein (APP). In two Molecular Psychiatry papers in 2012, we sought to determine the mechanism through which latrepirdine regulates APP metabolism and to determine, using an Alzheimer mouse model, whether latrepirdine provides protection from the toxicity associated with the accumulation of Aβ. In cultured cells, we provided evidence that latrepirdine stimulates MTOR- and ATG5-dependent autophagy, leading to the reduction of intracellular levels of APP metabolites, including Aβ. Consistent with this finding, we found that chronic latrepirdine administration resulted in increased levels of the biomarkers thought to correlate with autophagy activation in the brains of TgCRND8 (APP K670M, N671L, V717F) or wild-type mice, and that treatment was associated with abrogation of behavioral deficit, reduction in Aβ neuropathology, and prevention of autophagic failure among TgCRND8 mice. 相似文献